163 related articles for article (PubMed ID: 38256402)
21. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
22. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
24. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.
Khan S; Cameron S; Blaschke M; Moriconi F; Naz N; Amanzada A; Ramadori G; Malik IA
World J Gastroenterol; 2014 Mar; 20(11):2979-94. PubMed ID: 24659889
[TBL] [Abstract][Full Text] [Related]
25. Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.
Pranteda A; Piastra V; Serra M; Bernardini R; Lo Sardo F; Carpano S; Diodoro MG; Bartolazzi A; Milella M; Blandino G; Bossi G
Biomed Pharmacother; 2023 Nov; 167():115480. PubMed ID: 37713993
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
[TBL] [Abstract][Full Text] [Related]
27. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y
Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114
[TBL] [Abstract][Full Text] [Related]
28. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
[TBL] [Abstract][Full Text] [Related]
29. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
30. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
[TBL] [Abstract][Full Text] [Related]
31. High
Liu H; Zhang L; Wang Y; Wu R; Shen C; Li G; Shi S; Mao Y; Hua D
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374338
[No Abstract] [Full Text] [Related]
32. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
33. Real-world first-line treatment of patients with BRAF
Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
[TBL] [Abstract][Full Text] [Related]
34. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
[TBL] [Abstract][Full Text] [Related]
35. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
36. Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases.
Buchanan DD; Win AK; Walsh MD; Walters RJ; Clendenning M; Nagler B; Pearson SA; Macrae FA; Parry S; Arnold J; Winship I; Giles GG; Lindor NM; Potter JD; Hopper JL; Rosty C; Young JP; Jenkins MA
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):917-26. PubMed ID: 23462926
[TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.
Sun C; España S; Buges C; Layos L; Hierro C; Manzano JL
Clin Colorectal Cancer; 2022 Jun; 21(2):71-79. PubMed ID: 35277355
[TBL] [Abstract][Full Text] [Related]
39. Preliminary exploration of the effects of environmental factors on the microsatellite status of BRAF-mutated colorectal cancer.
Tian B; Chen G; Shi X; Jiang L; Jiang T; Li Q; Yuan L; Qin J
World J Surg Oncol; 2023 Aug; 21(1):264. PubMed ID: 37620872
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Analysis of Treatment Pathways in Patients With BRAF
Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
